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Initial phase I and II clinical trials with recombinant
human interleukin-12 have demonstrated the
therapeutic ef®cacy of this cytokine in early stage
cutaneous T cell lymphoma as compared with more
advanced stages such as the leukemic SeÂzary
syndrome. In an effort to optimize the use of recom-
binant human interleukin-12, using ¯ow cytometry
we studied the regulation of the interleukin-12 recep-
tor b1 (high af®nity chain) and b2 (chain necessary
for interleukin-12 signal transduction) on normal
volunteer CD4+ and CD8+ T cells and CD4+ and
CD8+ cells from eight patients with different degrees
of leukemic involvement with SeÂzary syndrome. The
b1 chain was not readily detectable on resting
normal and T cells from SeÂzary patients, but expres-
sion was induced following T cell activation with
phytohemagglutinin. Similarly, the b2 chain was not
detectable on resting normal volunteer T cells, but
could be induced following phytohemagglutinin
stimulation. Moreover, the b2 chain on normal
volunteer T cells was markedly upregulated follow-
ing short-term culture with interferon-g or recombi-
nant human interleukin-12. CD8+ T cells routinely
exhibited a greater expression of b2 than did CD4+
T cells. In marked contrast, both CD4+ and CD8+ T
cells from patients with SeÂzary syndrome and a high
tumor cell burden (> 50% circulating atypical SeÂzary
T cells) failed to express the b2 chain under any
culture conditions. Although, culture with anti-inter-
leukin-10 also markedly increased b2 expression on
normal volunteer T cells, this failed to induce
expression on either CD4+ or CD8+ T cells from
SeÂzary patients and a high tumor burden.
Investigation of patients with SeÂzary syndrome and a
low tumor cell burden (< 15% circulating SeÂzary T
cells) revealed a pattern of b2 expression that was
intermediate between advanced SeÂzary syndrome
and normal volunteers. Both CD4+ and CD8+
peripheral blood T cells from these earlier stage
patients were induced to express the b2 chain,
although at a lower frequency of positivity than T
cells from normals, following culture with phyto-
hemagglutinin, interferon-g, recombinant human
interleukin-12, or anti-interleukin-10. These results
indicate that short-term culture with interferon-g
and recombinant human interleukin-12 potently
upregulates b2 chain expression on T cells from
normal volunteers, whereas a similar, but less
marked effect occurs on T cells from SeÂzary
syndrome patients and a low circulating tumor cell
burden. In contrast, the b2 chain appears to be
suppressed on both CD4+ and CD8+ T cells from
SeÂzary patients with a heavy circulating tumor cell
burden and it is not induced by interferon-g or
recombinant human interleukin-12. Therefore,
recombinant human interleukin-12 is likely to be
most effective for early stage cutaneous T cell lym-
phoma due to a greater display of b2 receptors on
responding CD8+ anti-tumor cytotoxic T cells. Key
words: cytokine/interleukin-12 receptor/interleukin-12/
SeÂzary syndrome. J Invest Dermatol 117:119±127, 2001
C
utaneous T cell lymphoma (CTCL) is a clonally
derived malignant proliferation of skin-invasive
CD4+ T lymphocytes Edelson, 1980; Haynes et al,
1981; Weiss et al, 1985). Clinical manifestations of
CTCL can comprise a broad spectrum of ®ndings
ranging from limited cutaneous patches and plaques with no overt
peripheral blood or lymph node involvement to extensive skin
involvement with tumors or erythroderma with concomitant
blood, node or visceral disease (Murphy, 1988; Nickoloff et al,
1989). During disease progression a variety of immunologic
abnormalities have been identi®ed, including prominent defects
in cell-mediated immunity (Rook et al, 1993; Rook and Heald,
1995). These abnormalities are typically associated with the
depressed ability of peripheral blood cells to produce the T helper
(Th) type 1 cytokines, interferon (IFN) -g and interleukin (IL)-2
(Vowels et al, 1992, 1994; Rook et al, 1993). Moreover, profound
defects in the production of IL-12 have also been observed in more
advanced stages of disease (Rook et al, 1995). The pathogenesis of
these cytokine defects may be related to the excess production of
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Th2 cytokines (IL-4, -5, and -10) by the malignant clonal T cell
population, which can antagonize the function and production of
IL-12 and Th1 cytokines (Vowels et al, 1992, 1994; Rook et al,
1993, 1995; Rook and Heald, 1995).
It has become increasingly evident that CTCL is a disease that is
responsive at all stages to the use of biologic agents, including IFN
and retinoid compounds (Knobler et al, 1991; Gottlieb et al, 1996;
Fox et al, 1999). In this regard, we have recently completed a
successful phase I trial using recombinant human IL-12 (rhIL-12) to
treat CTCL. The results demonstrated a high level of therapeutic
activity of this cytokine, particularly for patients with either limited
or extensive patch or plaque type disease (Rook et al, 1999).
Regression of skin lesions appeared to be temporally associated
with marked intralesional in®ltrates of CD8+ cytotoxic T cells
(Rook et al, 1999). Nevertheless, patients with an extensive burden
of malignant CD4+ T cells, such as those with multiple tumor
nodules or those with SeÂzary syndrome, the variant exhibiting
erythroderma and circulating malignant T cells, displayed less
remarkable clinical responses to rhIL-12 (Rook et al, 1999).
Presently, IL-12 cell surface receptors on lymphocytes, which are
predominantly expressed on T, natural killer, and some dendritic
cells, have been identi®ed to consist of a b1 and a b2 subunit.
Although the expression of the b1 subunit has been shown to be
necessary for binding IL-12 (Zou et al, 1997), the expression of IL-
12 receptor (IL-12R) b2 is mandatory for IL-12 to signal and thus
for an IL-12 response to occur (Chua et al, 1995; Showe et al,
1999). In an effort to understand the mechanisms underlying the
diminished response rate to rhIL-12 among patients with a heavy
malignant T cell burden, components of the IL-12 signal
transduction pathway were examined (Showe et al, 1999). Initial
®ndings using RNAse protection assays indicated that malignant
CD4+ T cells obtained from the blood of patients with SeÂzary
syndrome had no detectable RNA transcripts for the IL-12 b2
chain, which is critical for intracellular signaling by IL-12 (Showe et
al, 1999). Furthermore, the malignant T cells failed to manifest
phosphorylation of Jak 2 and Stat 4 when cultured in vitro with high
concentrations of rhIL-12 (Showe et al, 1999). In contrast, CD4+ T
cells from normal volunteers had detectable transcripts for the b2
chain and exhibited intact IL-12 signal transduction pathways.
Moreover, CD8+ T cells obtained from either patients with CTCL
or normal volunteers had detectable phosphorylated Stat 4 when
cultured with rhIL-12, thus suggesting the presence of b2
expression by these cells (Showe et al, 1999). These observations
implied that rhIL-12 was active on normal CD4+ or CD8+ T cells
and that the therapeutic response of CTCL patients to rhIL-12 was
likely mediated through the induction of CD8+ anti-tumor
cytotoxic T cell activity. This conclusion was supported by biopsy
data of regressing lesions (Rook et al, 1999). In addition, these
results also provide a basis to explain the lack of response among
patients with advanced CTCL who typically have high numbers of
malignant CD4+ T cells and diminished numbers of circulating
CD8+ T cells.
Because the optimal use of rhIL-12 in CTCL depends upon a full
understanding of IL-12R regulation on these patients' diseased and
normal T lymphocytes, additional studies were undertaken to assess
the effects of important immune augmentatory cytokines on the
expression of IL-12R chains b1 and b2. Moreover, as the
malignant T cells from patients with CTCL are frequently
known to produce high concentrations of type 2 helper T cell
cytokines (Rook et al, 1995; Vowels et al, 1992), we also examined
the role of these cytokines on IL-12R expression.
MATERIALS AND METHODS
Patients Patients participating in this study were diagnosed with the
SeÂzary syndrome (Edelson, 1980), the leukemic form of CTCL, on the
basis of clinical, histopathologic, and immunohistologic criteria (Murphy,
1988). Characterization of patient circulating malignant T cells was
performed by analyzing 1 mm sections of formalin-®xed peripheral blood
buffy coats by the detection of mononuclear cells possessing cerebriform
nuclear morphology. In addition, ¯uorescence-activated cell sorting
(FACS) analysis was used speci®cally to select typical malignant clonal
populations that were CD4+/CD7± (Murphy, 1988). Using these two
techniques, two groups of patients with SeÂzary syndrome were studied.
One group, referred to as the high ``tumor burden'' group, consisted of
six patients with SeÂzary counts ranging from approximately 50% up to
99% of mononuclear cells, whereas the ``low tumor'' burden group
consisted of two patients with SeÂzary counts that were approximately
10±15% of mononuclear cells on each of the 3 different days that their
cells were studied. None of the patients were receiving cytotoxic drugs
or systemic or topical corticosteroids at the time of study. Donations of
blood by patients (n = 8) or normal volunteers (n = 8) in this study
conformed to IRB-approved protocol and informed consents were
obtained.
Peripheral blood mononuclear cell (PBMC) preparation and
culture criteria PBMC were prepared as described previously (Rook
et al, 1995). Brie¯y, venous blood was collected into heparinized syringes
using uniform standards for both SeÂzary syndrome patients and normal
volunteers. The blood was then diluted 2-fold with Dulbecco's
phosphate-buffered saline (BioWhittaker, Walkersville, MD), pH 7.2,
layered over Ficoll-Hypaque (Amersham, Uppsala, Sweden), and
centrifuged at 500 3 g for 30 min at room temperature. The interface
containing the mononuclear cell fraction was collected and cells were
washed twice with phosphate-buffered saline. Cells were used
immediately after puri®cation.
Cell cultures were set up at a ®nal concentration of 1 3 106 cells per
ml in RPMI 1640 media (Gibco-BRL, Grand Island, NY) supplemented
with 10% heat-inactivated fetal bovine serum, 200 mmol per liter L-
glutamine, and 100 U per ml penicillin-streptomycin for 70 h. Certain
cultures were supplemented with mitogen phytohemagglutinin (PHA)
(1 mg per ml or 2 mg per ml), predetermined concentrations of cytokines
(IL-12: 1 ng per ml; IFN-g: 1000 U per ml, IFN-a: 1000 U per ml, and
IL-18: 10 ng per ml) and/or IL-10 or IL-4 neutralizing antibody (10 mg
per ml).
Cell surface staining and ¯ow cytometric analysis of IL-12R subunit
b1 and b2 on T subset CD4+ and CD8+ cells Analysis of the
expression of IL-12R b1 and b2 subunits on CD4+ and CD8+ cells was
accomplished using ¯ow cytometric analysis. Approximately 106 PBMC
per sample were harvested from different cell cultures and washed twice
with washing solution (0.1% NaZ3, 0.1% gelatine, phosphate-buffered
saline, pH 7.4). Cells were then incubated with mouse IgG (Sigma, St
Louis, MO) for 10 min on ice to reduce nonspeci®c binding. Rat IgG2a
directed against IL-12R b1 (2B10, Hoffman-La Roche, Nutley, NJ) and
b2 (2B6, Hoffman-La Roche) subunits at concentrations of 3 and 2 mg,
respectively, per 50 ml phosphate-buffered saline containing 5% fetal
bovine serum and 0.1% NaZ3 was then added to the cells and incubated
at 4°C for 30 min. Puri®ed rat IgG2a (Sigma) at the same concentration
was used as an appropriate control antibody. Cells were subsequently
washed twice with washing media and incubated with goat serum
(Sigma, 20 ml) on ice for 10 min to block nonspeci®c binding. Finally,
phycoerythrin-labeled goat anti-rat IgG secondary antibody (BioSource
International, Camarillo, CA) was added at a concentration of 1:100
dilution.
To differentiate the expression of IL-12R b1 and b2 on CD4+ and
CD8+ subpopulation, cells were stained with ¯uorescein isothiocyanate-
labeled anti-CD4 (Pharmingen, San Diego, CA) and PerCP-labeled
anti-CD8 (Becton Dickinson, San Jose, CA) antibodies. Fluorescein
isothiocyanate- and PerCP-labeled mouse IgG were used as controls,
respectively. After washing, stained cells were directly analyzed on a
FACScan ¯ow cytometer (Becton Dickinson). Data were processed by
using the CELLQuest program (Becton Dickinson). Typically 10 000
cells in each sample were analyzed. The level of IL-12R b1 and b2
subunit expression was measured by gating on CD4+ or CD8+ cells and
was expressed as D mean ¯uorescent intensity as determined by the mean
¯uorescent intensity of the positive peak relative to that of an isotype
control or expressed as percentage positive cells.
Cytokines, antibodies, and reagents Rat antibodies against human
IL-12R b1 (2B10) and b2 (2B6) chains were gifts from Dr. David
Presky (Hoffman-La Roche, Nutley, NJ). Phycoerythrin-labeled goat
anti-rat antibody was purchased from BioSource International
(Camarillo, CA). Recombinant IFN (rIFN) -g and rIL-18 were
purchased from R&D Systems (Minneapolis, MN) and rIFN-a2a was
purchased from Hoffman-La Roche (Nutley, NJ). Rat and mouse IgG
isotype control and goat serum blocking reagents were purchased from
Sigma. Fluorescein isothiocyanate- and PerCP-labeled antibodies for
CD4+ and CD8+ cells were purchased from Pharmingen (San Diego,
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CA) and Becton Dickinson (San Jose, CA), respectively. Anti-IL-10
monoclonal antibody (12G8) and anti-IL-4 were a gift from Dr. Giorgio
Trinchieri of the Wistar Institute (Philadelphia, PA). rIL-12 was
provided by Dr. Stanley Wolfe of Genetics Institute (Andover, MA).
Statistical analysis The data on IL-12 receptor expression was
analyzed using an unpaired, two-tailed Student's t test or the Wilcoxon
ranked sum test for paired groups to determine the statistical signi®cance
of the data, and p < 0.05 was considered signi®cant.
RESULTS
Expression of IL-12R b1 on peripheral blood resting and
PHA-activated T cells from normal volunteers and patients
with SeÂzary syndrome IL-12R b1 expression was evaluated on
CD4+ and CD8+ T cells that were derived from the peripheral
blood of healthy volunteers. Using immuno¯uorescence staining
and subsequent ¯ow cytometric analysis, receptor expression was
examined on either freshly isolated cells or following activation
with different concentrations of PHA. Non-activated T cells had
very low level expression of IL-12R b1. Following 70 h of PHA
stimulation, IL-12R b1 expression on CD4+ and CD8+ T cells
increased signi®cantly in relation to the concentration of PHA,
with 2 mg per ml inducing greater IL-12R b1 expression than 1 mg
per ml (Fig 1A).
Examination of IL-12R b1 on T cells from SeÂzary syndrome
patients revealed results that were similar to those using T cells from
normal volunteers. IL-12R b1 could be detected on low numbers
of freshly isolated CD8+ T cells, but not CD4+ cells. Furthermore,
PHA activation enhanced the level of expression on CD8+ cells and
also induced detectable receptors on CD4+ T cells (Fig 1B).
Expression of IL-12R b2: Peripheral blood T cells from
SeÂzary syndrome patients reveal a stage-related defect in
expression IL-12R b2 expression was similarly examined on
normal volunteer and SeÂzary syndrome T cells that were either
freshly isolated or following 70 h of stimulation with PHA. IL-12R
b2 could not be readily detected on freshly isolated T cells from
normal volunteers. Both CD4+ and CD8+ T cells from normal
volunteers, however, were induced to express IL-12R b2
following 3 d of culture with PHA at either 1 or 2 mg per ml
(Fig 2A). Repeated studies of eight different normal volunteers
revealed that a higher percentage of CD8+ T cells in comparison
with CD4+ T cells were typically observed to express IL-12R b2.
Initial studies of T cells from patients with SeÂzary syndrome were
performed using peripheral blood T cells derived from six patients
who had a heavy leukemic burden with more than 50% of their
circulating T cells identi®ed by 1 mm section morphologic analysis
and by ¯ow cytometry (CD4+/CD7±) as malignant CD4+ T cells.
Paralleling the observations made with healthy volunteer T cells,
IL-12R b2 could not be detected on freshly isolated cells. In
contrast to cells from normal volunteers, both CD4+ and CD8+ T
cells from these advanced stage SeÂzary patients failed to express IL-
12R b2 following PHA stimulation (Fig 2B). In each analysis,
10,000 CD4+ or CD8+ cells were typically analyzed.
In an effort to determine if a stage-related defect in IL-12R b2
expression could be observed, T cells from two patients with SeÂzary
syndrome who exhibited a substantially smaller peripheral blood
tumor cell burden (10±15% SeÂzary T cells at the time of study
assessed by 1 mm section analysis and FACS) were also examined.
As demonstrated in Fig 2(C), IL-12R b2 expression could be
detected on both CD4+ and CD8+ T cells from such patients
following 70 h of culture of their cells in PHA (2 mg per ml). Thus,
SeÂzary syndrome patients with a more profound degree of leukemia
are unable to express IL-12R b2 on their T cells following mitogen
activation, whereas patients with fewer peripheral blood malignant
T cells did exhibit IL-12R b2 on their T cells following activation,
but, at a level lower than that of T cells from normal volunteers.
Modulatory effects of Th1 type cytokines on IL-12R b2
expression on T cells of normal volunteers In an effort to
understand the interactions of immune augmentatory cytokines
with IL-12 and the ability of these cytokines to modulate IL-12R
b2 expression, we examined the effects of Th1 type cytokines on
IL-12R b2 expression. Freshly isolated T cells from normal
volunteers were cultured with either a suboptimal dose of PHA
alone (1 mg per ml), or with combinations of cytokines with PHA
for 70 h followed by ¯ow cytometric analysis. Recombinant IL-12
at a concentration of 1 ng per ml induced high levels of expression
of IL-12R b2 receptors on both CD4+ and CD8+ cells from
healthy volunteers (Fig 3A). Furthermore, the percentage of cells
expressing IL-12 b2 was higher among CD8+ (26.7% 6 5.0)
(mean 6 SE) than on CD4+ T cells (16.3 6 5.0) p = 0.01.
Figure 1. (A) Expression of IL-12R subunit b1
on CD4+ and CD8+ T cells of normal healthy
donors and (B) on T cells from SeÂzary syndrome
patients with or without PHA stimulation. PBMC
were cultured in the absence (dotted line) or
presence of 1 mg per ml (solid line) or 2 mg per
ml (bold line) PHA for 70 h. Cells were then
harvested, washed, and stained with appropriate
antibodies as described in Materials and Methods. At
least 10,000 events were analyzed on a FACScan
¯ow cytometer. Histograms show the ¯uorescence
intensity for binding of anti-b1 to CD4+ or CD8-
gated T+ cells in representative individuals. Data
are expressed as percent positive cells expressing
IL-12R subunit b1.
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Addition of excess IFN-g neutralizing antibodies to cultures
containing IL-12 failed to signi®cantly inhibit the upmodulation
of IL-12R b2 receptors by IL-12 suggesting that IL-12 probably
exerts IFN-g independent effects on receptor modulation (data not
shown).
Similar observations to upmodulate IL-12R b2 receptors were
made when normal cells were cultured with recombinant IFN-g at
a concentration of 1000 units per ml. IFN-g induced easily
detectable levels of IL-12R b2 on CD4+ and CD8+ T cells
(Fig 3B). At the concentrations used, the effect of IFN-g to induce
IL-12R b2 was consistently more potent than that of rIL-12 as
demonstrated in eight consecutive experiments using cells from
eight different donors.
Because previous scienti®c reports have indicated that rIL-12 and
IL-18 exhibit synergistic effects in vitro and in vivo, particularly in
regard to IFN-g induction and anti-tumor immunity (Coughlin et
al, 1998; Yamanaka et al, 1999), the combined effect of these two
cytokines on IL-12R b2 was examined. IL-12 and IL-18 together
at concentrations of 1 ng per ml and 10 ng per ml, respectively,
induced detectable IL-12R b2 (Fig 4). Nevertheless, the level of
induction was no greater than with IL-12 alone, indicating a lack of
synergistic or additive effect of these two cytokines in our system.
rIFN-a2a was also studied for its IL-12R b2 inducing effects.
When used in a range of concentrations from 10 units per ml up to
1000 units per ml, IFN-a inconsistently induced low levels of
detectable IL-12R b2 on normal T cells in two of ®ve experiments
(data not shown). Thus, in three of ®ve experiments IFN-a failed
to induce detectable levels of IL-12R b2 on T cells from normal
volunteers.
Failure to induce IL-12R b2 on T cells from SeÂzary
syndrome patients with large numbers of circulating
malignant T cells In marked contrast to observations with
normal volunteer cells, IL-12R b2 could not be induced on the
surface of T cells from patients with SeÂzary syndrome and a heavy
malignant cell burden (greater than 50% circulating malignant T
cells) regardless of the cytokines used in the cell culture system.
Examination by FACS of at least 10,000 CD4+ or CD8+ T cells
revealed that incubation of these patients' peripheral blood T cells
with various concentrations of rIL-12, IL-18, IFN-g or IFN-a plus
PHA 1 mg per ml for 70 h failed to induce detectable IL-12R b2
on either CD4+ or CD8+ T cells (Fig 5A, B). Culture of patient T
cells for shorter or longer periods (2±5 d) with cytokines and PHA
also failed to result in detectable IL-12R b2 expression (data not
shown).
Successful induction of IL-12R b2 on T cells from SeÂzary
syndrome patients who manifest smaller numbers of
circulating tumor cells In contrast to results obtained using T
cells from more advanced SeÂzary syndrome patients, T cells from
patients with a smaller tumor cell burden did have IL-12R b2
upregulated on the cell surface following culture with either IFN-g
or rhIL-12. A representative example using a patient's cells who
had approximately 15% circulating malignant T cells as assessed by
1 mm section analysis of buffy coats and by FACS is shown in
Fig 6(A) following 70 h of culture in 1 ng per ml of rhIL-12; this
demonstrates that this patient's CD4+ and CD8+ T cells had
detectable expression of IL-12R b2. A similar effect to induce
expression of IL-12R b2 was observed when T cells were cultured
for 70 h in IFN-g (Fig 6B). As observed with cells from normal
volunteers, the IL-12R b2 inducing effect of rIL-12 appeared to be
consistently less potent than the effect of IFN-g.
Neutralization of IL-10 signi®cantly increases the expression
of IL-12R b2 on T cells of normal donors, but not on those
of patients with SeÂzary syndrome As one of the characteristics
Figure 2. Expression of IL-12R subunit b2 on
CD4+ and CD8+ T cells from (A) healthy donors,
(B) from SeÂzary patients with a high circulating
tumor burden, and (C) from SeÂzary patients with
a low circulating tumor burden with or without
PHA stimulation. PBMC were cultured in the
absence of PHA (solid line) or with 2 mg PHA
per ml (bold line) for 70 h. Cells were then
harvested, washed, and stained with appropriate
antibodies as described in Materials and Methods.
The respective dot plots reveal percent of CD4+
and CD8+ T cells expressing IL-12R subunit b2
after PHA.
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of SeÂzary cells is the production of Th2 cytokines, including IL-10
and IL-4 (Nickoloff et al, 1994; Saed et al, 1994; Dummer et al,
1996, 1998; Mori and Prager, 1997; Rook et al, 1999) we elected
to evaluate the role of IL-10 on the expression of IL-12R b2 on
SeÂzary T cells and normal healthy donor cells by using IL-10
neutralizing antibody to deplete endogenous IL-10. The presence
of IL-10 neutralizing antibody in PHA stimulated cultures
signi®cantly increased the expression of IL-12R b2 on both
CD4+ and CD8+ T cells from healthy donors (Fig 7A). Similarly,
neutralization of IL-10 augmented expression of IL-12R b2 on T
cells from SeÂzary patients with a lower circulating number of
malignant T cells (Fig 7C). Nevertheless, the effect was less striking
in comparison with that observed with cells from normal donors. In
marked contrast; however, neutralization of IL-10 had no effect on
IL-12R b2 expression on T cells from SeÂzary syndrome patients
with a high number of circulating malignant T cells (Fig 7B).
Moreover, addition of rhIL-12 along with anti-IL-10 also failed to
result in the induction of IL-12R b2 expression on these patients'
cells (data not shown).
Furthermore, in an effort to determine if excess production of
the Th2 cytokine IL-4 was playing a part in the suppression of IL-
12R b2 on T cells from patients with a heavy malignant cell
burden, T cells from such patients were also cultured with
neutralizing anti-IL-4 antibody during PHA stimulation. The
neutralization of IL-4 also failed to induce IL-12R b2 expression
on either CD4+ or CD8+ T cells from these patients as shown in
Fig 8. In each case, at least 10,000 CD4+ or CD8+ cells were
examined by FACS.
DISCUSSION
Previous investigations have revealed the inability to detect mRNA
for the IL-12R b2 subunit within malignant CD4+ T cells isolated
from the blood of patients with SeÂzary syndrome (Showe et al,
Figure 3. Effects of IL-12 and IFN-g on the
expression of IL-12R b2 on CD4+ and CD8+
T cells of normal healthy donors. (A) Cells
cultured with low-dose PHA (1 mg per ml) were
stimulated with IL-12 (1 ng per ml). Seventy
hours later, cells were processed and stained for
¯ow cytometric analysis of the expression of IL-
12R b2 as described in Materials and Methods.
Solid lines represent cells with PHA, but without
any IL-12 stimulation. Bold lines represent cells
that have been stimulated with PHA plus IL-12.
Data are expressed as percent positive cells
expressing IL-12R subunit b2. (B) Effects of IFN-
g on the expression of IL-12R b2 on CD4+ and
CD8+ T cells of normal healthy donors. Cells
cultured with low-dose PHA (1 mg per ml) were
stimulated with IFN-g (1000 U per ml) for 70 h
prior to processing and staining for ¯ow
cytometric analysis of the expression of IL-12R
b2. Solid lines represent cells without any IFN-g
stimulation. Bold lines represent cells that have
been stimulated with IFN-g.
Figure 4. Effects of combined treatment
with IL-12 and IL-18 on the expression of
IL-12R b2 on CD4+ and CD8+ T cells from
normal healthy donors. PHA (1 mg per ml)
treated cells were stimulated with IL-12 (1 ng per
ml) and IL-18 (10 ng per ml). Seventy hours later,
cells were processed and stained for ¯ow
cytometric analysis of expression of IL-12R b2.
Solid lines represent cells without any IL-12 and
IL-18 stimulation. Bold lines represent cells that
have been stimulated with IL-12 and IL-18. Data
are expressed as percent positive cells expressing
IL-12R subunit b2.
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1999). This study using FACS analysis to assess expression of the b1
and b2 subunits at the cell surface con®rmed these earlier ®ndings.
T cells isolated from the blood of normal volunteers could be
induced to express both b1 and b2 following PHA activation and
culture with either IFN-g or IL-12. At the doses used, IFN-g was
consistently more potent than IL-12 in its ability to induce the b2
subunit. Moreover, a greater degree of expression of the b2 subunit
was observed on CD8+ as opposed to CD4+ T cells. In contrast,
CD4+ T cells isolated from patients with advanced SeÂzary
syndrome failed to express the b2 subunit under any of the
Figure 5. Effects of IL-12 (A) and IFN-g (B) on
the expression of the IL-12R b2 subunit on
CD4+ and CD8+ T cells of advanced SeÂzary
syndrome patients with a high percentage of
circulating malignant T cells. Cells cultured with
PHA (1 mg per ml) were stimulated with IL-12
(1 ng per ml) or IFN-g (1000 U per ml). Seventy
hours later, cells were stained and analyzed by
¯ow cytometry for the expression of IL-12R b2
on T cell subsets by gating on CD4+ or CD8+
cells as described in Materials and Methods.
Typically, 10,000 CD4+ or CD8+ cells in each
sample were analyzed. Solid lines represent cells
without any cytokine stimulation. Bold lines
represent cells that have been stimulated with IL-
12 or IFN-g as indicated. Data are expressed as
percent positive cells expressing IL-12R subunit
b2.
Figure 6. Effects of IL-12 and IFN g on the
expression of IL-12R b2 on CD4+ and CD8+
T cells of SeÂzary syndrome patients with a
low percentage of circulating malignant
cells. (A) Cells cultured in the presence of low-
dose PHA (1 mg per ml) were stimulated with IL-
12 (1 ng per ml). Seventy hours later, cells were
processed and stained for ¯ow cytometric analysis
of the expression of IL-12R b2 as described in
Materials and Methods. Solid lines represent cells
without any IL-12 stimulation. Bold lines
represent cells that have been stimulated with IL-
12. Data are expressed as percent positive cells
expressing IL-12R subunit b2. (B) Effects of IFN-
g on the expression of IL-12R b2 on CD4+ and
CD8+ T cells of SeÂzary syndrome patients with a
low percentage of circulating malignant cells. Cells
cultured in the presence of low-dose PHA (1 mg
per ml) were stimulated with IFN-g (1000 units
per ml). Seventy hours later, cells were processed
and stained for ¯ow cytometric analysis of the
expression of IL-12R b2. Solid lines represent
cells without any cytokine stimulation. Bold lines
represent cells that have been stimulated with
IFN-g.
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conditions used. Thus, simultaneous culture of patient CD4+ cells
following PHA activation with cytokines or groups of cytokines
known to enhance b2 expression (Rogge et al, 1997; Szabo et al,
1997; Gately et al, 1998; Chang et al, 1999; Sinigaglia et al, 1999;
Trinchieri and Scott, 1999), including IFN-a or -g, IL-12, IL-12
with IFN-g, or IL-12 with IL-18 did not stimulate the expression
of detectable b2.
Our studies con®rm the ability to upregulate the expression of
the b2 subunit by culture of T cells from normal volunteers with
either recombinant IFN-g or IL-12 (Showe et al, 1999); however,
we failed to con®rm the marked positive modulatory effects
reported by others (Rogge et al, 1999) of recombinant IFN-a on
the expression of the b2 subunit. In contrast to our in vitro methods,
which employed PHA activation of T cells, a number of
experimental systems used by others employed anti-CD3 to
preactivate T cells (Rogge et al, 1999). Nevertheless, in a manner
comparable with Rogge et al (1999), who demonstrated prominent
effects of IFN-a to upregulate the b2 subunit and to enhance Th1
differentiation (Rogge et al, 1997, 1998), we utilized similar
methodology by preactivating T cells with PHA, yet failed to
document any effects of IFN-a on b2 expression in three of ®ve
experiments. Moreover, the effect of IL-12 to upregulate b2
expression was not altered by the simultaneous addition of IL-18 to
the IL-12 containing culture system; therefore suggesting that
synergism exhibited by this combination of cytokines to augment
cell-mediated immunity in a number of different models may occur
by mechanisms that are independent of IL-12R expression
induction. One mechanism whereby IL-18 and IL-12 synergize
Figure 7. Effects of IL-10 neutralizing antibodies
on the expression of IL-12R b2 of a
representative normal healthy donor (A), a SeÂzary
syndrome patient with a high circulating tumor
cell burden (B), and a patient with a low
percentage of circulating malignant cells (C). PHA
(1 mg per ml) treated cells were cultured with
neutralizing antibodies against IL-10 (anti-IL-10:
10 mg per ml) for 70 h prior to the staining
process. IL-12R b2 expression on T cells was
analyzed by ¯ow cytometry by gating on CD4+
or CD8+ cells as described in Materials and
Methods. Solid lines represent cells without anti-
IL-10 added. Bold lines represent cells that have
been cultured with anti-IL-10 as indicated. Data
are expressed as percent positive cells expressing
IL-12R subunit b2.
Figure 8. Effects of IL-4 neutralizing
antibodies on the expression of IL-12R b2 on
CD4+ and CD8+ T cells from a SeÂzary
syndrome patient with a high circulating
tumor cell burden. PHA (1 mg per ml) treated
cells were cultured with neutralizing antibodies
against IL-4 (anti-IL-4: 10 mg per ml) for 70 h
prior to the staining process. IL-12R b2
expression on T cells was analyzed by ¯ow
cytometry by gating on 10,000 CD4+ or CD8+
cells. Solid lines represent cells without anti-IL-4
added. Bold lines represent cells that have been
cultured with anti-IL-4 as indicated. Data are
expressed as percent positive cells expressing IL-
12R subunit b2.
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is through the enhanced production of IFN-g. It is possible that the
IFN-g induction has the potential of secondarily augmenting IL-
12R expression (Yamanaka et al, 1999). Alternatively, it is likely
that IL-12 and IL-18 produce synergistic effects through inde-
pendent T cell activation pathways.
The differential expression of the b2 subunit of the IL-12R is a
feature that distinguishes Th1 from Th2 T cells (Rogge et al, 1997,
1998). Th1 cells exhibit the b2 subunit at the cell surface and are
thus able to signal and respond to IL-12. In contrast, Th2 cells do
not express the b2 subunit and are unresponsive to the effects of IL-
12. Substantial data have been developed suggesting that CD4+
SeÂzary T cells are derived from Th2 cells (Rook et al, 1993; Vowels
et al, 1994; Dummer et al, 1996, 1998). Therefore, previous results
that these cells fail to manifest detectable cytoplasmic mRNA for
b2 transcripts as well as this study data that there is no b2 protein at
the cell surface, further supports the Th2 lineage of these cells.
More surprising was the ®nding that b2 was undetectable on the
surface of patient CD8+ T cells in all but two cases. These latter
cases were typi®ed by less advanced disease characterized by a
reasonably low peripheral blood tumor cell burden with 10±15%
circulating SeÂzary cells in comparison with the remainder of the
SeÂzary syndrome patients studied who all had 50% or greater
circulating SeÂzary cells. A potential mechanism underlying this
observation is the production of a soluble factor by the malignant T
cells that suppresses the expression of the b2 subunit on the normal
lymphoid populations of the patients. Soluble factors that have been
implicated in the suppression of IL-12 activity and might play a part
in this process include IL-10, IL-4, prostaglandin E2, and
transforming growth factor-b (Pardoux et al, 1997; Gorham et al,
1998; Himmelrich et al, 1998; Wu et al, 1998). Our results with
lymphoid cells from normal volunteers suggested that endogenous
IL-10 has a potent negative modulatory effect on b2 expression.
Nevertheless, culture of advanced SeÂzary syndrome patient T cells
with either anti-IL-10 or anti-IL-4 neutralizing antibodies, with or
without IL-12, failed to induce detectable b2 on these cells. The
role of transforming growth factor-b or prostaglandin E2 were not
examined in our study. Whether increased production of these
factors occurs in advanced CTCL and whether they play a part in
the suppression of b2 deserves additional investigation.
Our observations of absent b2 expression on T cells derived from
patients with more advanced stage SeÂzary syndrome have important
implications for the therapeutic use of IL-12 for CTCL. These and
earlier ®ndings suggest that the malignant CD4+ SeÂzary T cells are
likely to be refractory to the direct biologic effects of IL-12 (Showe
et al, 1999). In fact, when such cells are cultured with high
concentrations of IL-12, signal transduction does not occur as
evidenced by the absence of detectable phosphorylated Stat 4
(Showe et al, 1999). In contrast, CD4+ T cells derived from normal
volunteers routinely have detectable phosphorylated Stat 4 after
culture with IL-12 (Showe et al, 1999). In addition, expression of
b2 appears to be suppressed on CD8+ T cells derived from the
blood of more advanced SeÂzary patients. Thus, a greater display of
b2 on CD8+ T cells from patients with a smaller burden of
malignant T cells suggests that earlier stage patients should be more
responsive to the effects of IL-12. Results from a recent phase I
study have supported this concept with a higher response rate being
noted among patients with earlier stage disease and with greater
numbers of circulating CD8+ T cells (Rook et al, 1999). It is hoped
that future trials will con®rm the appropriate patient populations
that should be targeted with IL-12 therapy and whether the
concomitant use of other cytokines with IL-12 will lead to a greater
degree of clinical ef®cacy.
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